Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Practices of therapeutic drug monitoring in tuberculosis: an international survey.
Margineanu I, Akkerman O, Cattaneo D, Goletti D, Marriott DJE, Migliori GB, Mirzayev F, Peloquin CA, Stienstra Y, Alffenaar JW. Margineanu I, et al. Among authors: alffenaar jw. Eur Respir J. 2022 Apr 14;59(4):2102787. doi: 10.1183/13993003.02787-2021. Print 2022 Apr. Eur Respir J. 2022. PMID: 35086830 Free PMC article.
Rifampicin and moxifloxacin for tuberculous meningitis.
Akkerman O, Pranger A, van Altena R, van der Werf T, Alffenaar JW. Akkerman O, et al. Among authors: alffenaar jw. Lancet Infect Dis. 2013 Jul;13(7):568-9. doi: 10.1016/S1473-3099(13)70101-4. Lancet Infect Dis. 2013. PMID: 23809221 No abstract available.
Drug concentration in lung tissue in multidrug-resistant tuberculosis.
Akkerman OW, van Altena R, Klinkenberg T, Brouwers AH, Bongaerts AH, van der Werf TS, Alffenaar JW. Akkerman OW, et al. Among authors: alffenaar jw. Eur Respir J. 2013 Dec;42(6):1750-2. doi: 10.1183/09031936.00047413. Eur Respir J. 2013. PMID: 24293422 Free article. No abstract available.
Raltegravir and rifampicin in patients with HIV and tuberculosis.
Klis S, Daskapan A, Akkerman OW, Alffenaar JW, Stienstra Y. Klis S, et al. Among authors: alffenaar jw. Lancet Infect Dis. 2014 Nov;14(11):1046-1047. doi: 10.1016/S1473-3099(14)70977-6. Epub 2014 Oct 19. Lancet Infect Dis. 2014. PMID: 25444405 No abstract available.
Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. Tiberi S, et al. Among authors: alffenaar jw. Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. Clin Infect Dis. 2016. PMID: 26908794 No abstract available.
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. Tiberi S, et al. Among authors: alffenaar jw. Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10. Eur Respir J. 2016. PMID: 26965290 Free article.
403 results